Monoclonal Antibody Infusions for Outpatient Management of Mild-Moderate COVID-19
Annals of Pharmacotherapy · 2024
DOI: 10.1177/10600280231222465 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Pharmacotherapy, 2024. Verfasst von Hannah B Knox und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Services, Ralph H. Johnson Veterans Affairs Health Care System, Charleston, SC, USA. Hauptthemen laut MEDLINE: COVID-19, Antibodies, Monoclonal, COVID-19 Drug Treatment. Die Arbeit nennt 22 Literaturangaben.
Abstract (Originalsprache)
Background
The COVID-19 pandemic has led to a rapid, exponential increase in hospitalizations and morbidity/mortality. In November 2020, the Food and Drug Administration (FDA) issued Emergency Use Authorizations (EUAs) permitting administration of the first monoclonal antibodies (mAb) for outpatient treatment of COVID-19. Early data showed a reduction in COVID-19-related hospitalizations with few adverse events. However, since these treatments are only authorized under an EUA, real-world data are minimal.
Objective
To assess efficacy and safety of mAbs in a veteran population.
Methods
This retrospective study analyzed veterans at the Ralph H. Johnson Veterans Affairs Health Care System with mild-moderate COVID-19 and screened for mAb eligibility between December 1, 2020, and October 31, 2021. The primary outcome was hospitalizations and/or emergency department (ED) visits within 30 days. Secondary outcomes included 30-day mortality and post-COVID-19 conditions. Adverse events were also evaluated. Outcomes were compared between mAb-treated patients and eligible veterans who were not treated.
Results
There were 296 and 275 veterans in the mAb and control groups, respectively. No statistically significant difference was found for the primary outcome overall (25.7% vs 25.1%; P = 0.87), nor for COVID-19-related return visits or hospitalizations (13.9% v. 16%; P = 0.4). However, the mAb group had more return ED visits ( P = 0.35), and the control group had significantly more hospitalizations ( P = 0.02). Vaccinated veterans who received an mAb had fewer return visits and hospitalizations ( P = 0.01). More mAb-treated veterans experienced post-COVID-19 conditions. No difference in mortality was found. Four nonsevere adverse events occurred after the mAb therapy. Conclusion and relevance: Overall, the mAbs appeared safe and effective. Sicker, higher-risk mAb-treated veterans faired similarly to less-sick, high-risk veterans not treated. Those who were vaccinated seemed to benefit the most from mAb therapy. Future prospective studies with more matched groups are needed to assess full benefits and risks of mAbs shown to neutralize the predominant variants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Services, Ralph H. Johnson Veterans Affairs Health Care System, Charleston, SC, USA.
- Department of Emergency Medicine, Ralph H. Johnson Veterans Affairs Health Care System, Charleston, SC, USA.
- Department of Emergency Medicine, College of Medicine, Medical University of South Carolina, Charleston, SC, USA.
ORCID-Profile: Lisa A Dykes
Zitieren
APA
Knox, H. B., Dykes, L. A., Scott, L. A., Presley, B. C., & Lambert, L. C. (2024). Monoclonal Antibody Infusions for Outpatient Management of Mild-Moderate COVID-19. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280231222465
Vancouver
Knox HB, Dykes LA, Scott LA, Presley BC, Lambert LC. Monoclonal Antibody Infusions for Outpatient Management of Mild-Moderate COVID-19. Annals of Pharmacotherapy. 2024. doi:10.1177/10600280231222465
BibTeX
@article{Knox2024,
author = {Knox, Hannah B and Dykes, Lisa A and Scott, Lancer A and Presley, Bradley C and Lambert, Lara C},
title = {Monoclonal Antibody Infusions for Outpatient Management of Mild-Moderate COVID-19},
journal = {Annals of Pharmacotherapy},
year = {2024},
doi = {10.1177/10600280231222465}
}
EUVIMED